<DOC>
	<DOC>NCT02767596</DOC>
	<brief_summary>The study aims to examine the effectiveness of the short acting GLP-1 analog, Lixisenatide to achieve glycemic control in type 2 diabetes patients, in patients with failure of long acting GLP-1 analog. Patients who fail to achieve significant improvement in diabetes control on basal insulin and Liraglutide will be switched to basal insulin and lixisenatide treatment for 12 weeks. The primary outcomes will be changes in HBA1C and weight.</brief_summary>
	<brief_title>Evaluation of Lixisenatide Efficacy in Diabetes Mellitus Type 2 With Failure of Other GLP-1 Analog</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Type Diabetes Mellitus on combination of basal insulin therapy and GLP1 analog, with secondary failure of nonfasting glycemic control Pregnant or lactating woman Renal failure (eGFR&lt;30)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Type 2 Diabetes Mellitus</keyword>
	<keyword>treatment</keyword>
	<keyword>GLP-1</keyword>
</DOC>